Bio-Techne (BSP:T1CH34) Debt-to-Revenue : 0.51 (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Bio-Techne Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Bio-Techne's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was R$62 Mil. Bio-Techne's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was R$2,661 Mil. Bio-Techne's annualized Revenue for the quarter that ended in Dec. 2023 was R$5,343 Mil. Bio-Techne's annualized Debt-to-Revenue for the quarter that ended in Dec. 2023 was 0.51.

Bio-Techne Debt-to-Revenue Historical Data

The historical data trend for Bio-Techne's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bio-Techne Debt-to-Revenue Chart

Bio-Techne Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Debt-to-Revenue

Get a 7-Day Free Trial

0.71

0.59

0.45

0.30

0.40

Bio-Techne Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Revenue	Get a 7-Day Free Trial															0.27	0.40	0.38	0.50	0.51

Competitive Comparison of Bio-Techne's Debt-to-Revenue

For the Biotechnology subindustry, Bio-Techne's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bio-Techne's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bio-Techne's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Bio-Techne's Debt-to-Revenue falls into.

Bio-Techne Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Bio-Techne's Debt-to-Revenue for the fiscal year that ended in Jun. 2023 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(54.357	+	2153.907)	/	5517.21
	=	0.40

Bio-Techne's annualized Debt-to-Revenue for the quarter that ended in Dec. 2023 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(62.09	+	2660.724)	/	5342.704
	=	0.51

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Dec. 2023) Revenue data.

Bio-Techne Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Bio-Techne's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Bio-Techne (BSP:T1CH34) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bio-Techne Corp (BSP:T1CH34) » Definitions » Debt-to-Revenue

Comparable Companies

Traded in Other Exchanges

TECH:USA TE1:Germany

Address

614 McKinley Place N.E., Minneapolis, MN, USA, 55413

Website

https://www.bio-techne.com

Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.

Bio-Techne (BSP:T1CH34) Headlines

No Headlines